The 20 Best Clear Cell Sarcoma Doctors near Jersey City, NJ

William Huang is a Urologist in New York, New York. Dr. Huang is rated as a Distinguished provider by MediFind in the treatment of Clear Cell Sarcoma. His top areas of expertise are Renal Cell Carcinoma (RCC), Bladder Cancer, Prostate Cancer, Nephrectomy, and Cystectomy.

James Wysock is a Urologist in New York, New York. Dr. Wysock is rated as an Advanced provider by MediFind in the treatment of Clear Cell Sarcoma. His top areas of expertise are Prostate Cancer, Urachal Cyst, Renal Cell Carcinoma (RCC), Nephrectomy, and Prostatectomy.

Guido Dalbagni is a Urologist in New York, New York. Dr. Dalbagni is rated as a Distinguished provider by MediFind in the treatment of Clear Cell Sarcoma. His top areas of expertise are Bladder Cancer, Urothelial Cancer, Upper Tract Urothelial Carcinoma (UTUC), Cystectomy, and Nephrectomy. Dr. Dalbagni is currently accepting new patients.

Thomas Bradley, MD, FACP, is Associate Professor of Medicine at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell. As System Head for Genitourinary Cancers for the Northwell Health Cancer Institute, Dr. Bradley has special expertise in the management of prostate, kidney, bladder, and testicular cancers. Board certified in Internal Medicine, Hematology and Medical Oncology, Dr. Bradley maintains an active practice where he focusses on providing compassionate, personalized, evidence-based multi-disciplinary care. Dr. Bradley has a keen interest in the education of future physicians as evidenced by his directorship of the Fellowship program in Hematology and Medical Oncology for many years. His research work as principal investigator for numerous drug trials and multiple collaborations has resulted in dozens of publications and abstracts. Dr. Bradley earned his medical degree from the University of Monterrey School of Medicine. He trained in internal medicine as well as hematology and medical oncology at the State University of New York at Downstate Medical Center. Dr. Bradley is an active member of the American Society of Hematology, American Society of Clinical Oncology, American Association for Cancer Research and the American College of Physicians. Dr. Bradley is rated as a Distinguished provider by MediFind in the treatment of Clear Cell Sarcoma. His top areas of expertise are Upper Tract Urothelial Carcinoma (UTUC), Clear Cell Sarcoma, Chromophobe Renal Cell Carcinoma, WT1-Related Wilms Tumor Syndromes, and Bone Marrow Aspiration.

Anthony Corcoran is a Urologist in New York, New York. Dr. Corcoran is rated as a Distinguished provider by MediFind in the treatment of Clear Cell Sarcoma. His top areas of expertise are Muscle Invasive Bladder Cancer, Prostate Cancer, Renal Cell Carcinoma (RCC), Nephrectomy, and Vasectomy.

Michael Palese is a Urologist in New York, New York. Dr. Palese is rated as a Distinguished provider by MediFind in the treatment of Clear Cell Sarcoma. His top areas of expertise are Renal Cell Carcinoma (RCC), Enlarged Prostate (BPH), Wilms Tumor, Nephrectomy, and Reconstructive Urology Surgery.

Daniel Cho is an Oncologist in New York, New York. Dr. Cho is rated as a Distinguished provider by MediFind in the treatment of Clear Cell Sarcoma. His top areas of expertise are Renal Cell Carcinoma (RCC), Chromophobe Renal Cell Carcinoma, WT1-Related Wilms Tumor Syndromes, and Familial Wilms Tumor 2.

David Silver is a Urologist in Brooklyn, New York. Dr. Silver is rated as a Distinguished provider by MediFind in the treatment of Clear Cell Sarcoma. His top areas of expertise are Clear Cell Sarcoma, Chromophobe Renal Cell Carcinoma, WT1-Related Wilms Tumor Syndromes, Vasectomy, and Nephrectomy.

Dr Steven Berman has been in practice for 25 years specializing in General Urology. Dr. Berman is rated as an Experienced provider by MediFind in the treatment of Clear Cell Sarcoma. His top areas of expertise are Enlarged Prostate (BPH), Prostate Cancer, Familial Prostate Cancer, and Urinary Tract Infection in Children.

Jasmine Francis is an Oncologist in New York, New York. Dr. Francis is rated as an Advanced provider by MediFind in the treatment of Clear Cell Sarcoma. Her top areas of expertise are Retinoblastoma, Melanoma of the Eye, Metastatic Uveal Melanoma, Vitrectomy, and Liver Embolization. Dr. Francis is currently accepting new patients.

Lee Richstone, MD is the Chairman of Urology and Director of Urology Services for the Western Region. He is also Director of Laparoscopic and Robotic Surgery at Lenox Hill Hospital and System Vice Chairman for Education for Northwell Health Urology. Dr. Richstone is Professor of Urology at The Hofstra-Northwell School of Medicine. Dr. Richstone completed medical school at the Cornell University Medical College in New York City. There he won early acceptance into Alpha Omega Alpha (AOA), the prestigious national medical honor society. He pursued his urologic training and chief residency at New York Presbyterian (Weill-Cornell) and Memorial Sloan Kettering hospitals. Dr. Richstone completed his fellowship training in urologic laparoscopic and robotic surgery and joined the North Shore Long Island Jewish Health System in 2007 as Director of Laparoscopic and Robotic Surgery. He then served as Chief of Urology for the North Shore University Hospital, then Chief of Urology at the Long Island Jewish Medical Center, before assuming the role of Chairman of Urology at Lenox Hill Hospital in Manhattan. Dr. Richstone is an internationally recognized urologic surgeon who has helped pioneer laparoscopic and robotic surgery for cancer of the prostate, kidney and bladder, as well as for various forms of urinary obstructions. He has over 90 peer-reviewed publications in leading national and international journals including The Journal of Urology, Urology, The British Journal of Urology, The Journal of Endourology, Cancer, and Cell.Dr. Richstone is a robotic surgery specialist having performed well over 1000 operations. This includes surgeries for prostate, kidney and bladder cancer and complex neobladder reconstructions completely robotically. His focus is on preserving urinary continence and sexual function. Dr. Richstone has also pioneered Laparoendoscopic Single Site Surgery (LESS), where entire laparoscopic operations are performed only through the belly button. Dr. Richstone is one of only a few surgeons in the United States to have performed single site partial nephrectomy and prostatectomy.Dr. Richstone is a member of the Society of Urologic Oncology (SUO), the America Urological Association (AUA), and the Endourological Society (EUS). Dr. Richstone is the recipient of numerous honors and awards, including acceptance into Alpha Omega Alpha (AOA), the E. Darracott Vaughan Prize for Excellence in Urology (2000), The Ferdinand C. Valentine Urology Essay Prize (First Place, 2005), The American Urological Association-Ambrose Reed Socioeconomic Essay Contest (First Place, 2005), and the Weill-Cornell Distinguished House Officer Award (2005). Dr. Richstone was awarded the Stryker and Nagamatsu Fellowship (2007), and won first prize at the Endourology Society Fellowship Paper Award the same year. Dr. Richstone won first prize at the AUA Research Foundation for Outstanding Research awarded at the 2010 AUA National Meeting in San Francisco. Dr. Richstone is rated as an Advanced provider by MediFind in the treatment of Clear Cell Sarcoma. His top areas of expertise are Bladder Cancer, Renal Cell Carcinoma (RCC), Muscle Invasive Bladder Cancer, Cystectomy, and Nephrectomy.

Ariel Schulman is a Urologist in Brooklyn, New York. Dr. Schulman is rated as an Experienced provider by MediFind in the treatment of Clear Cell Sarcoma. His top areas of expertise are Prostate Cancer, Enlarged Prostate (BPH), Bladder Cancer, Prostatectomy, and Nephrectomy.

James McKiernan, MD, is the John K. Lattimer Professor of Urology and CEO of ColumbiaDoctors. He is also Senior Vice Dean for Clinical Affairs for Columbia University Vagelos College of Physicians and Surgeons. Dr. McKiernan graduated from Johns Hopkins University with a BA in biology and received his MD from Columbia University College of Physicians and Surgeons. He completed his training in urology and general surgery at NewYork-Presbyterian Hospital, followed by a urologic surgical oncology fellowship at Memorial Sloan-Kettering Cancer Center. Dr. McKiernan's clinical practice is focused on urologic oncology and particularly on surgical therapy in high-risk patients with bladder and kidney cancers. Dr. McKiernan evaluates and treats over 1,000 patients with bladder cancer every year. His research, funded by NIH and biotechnology industry grants, focuses on developing novel therapeutics for bladder cancer treatment as well as comparative effectiveness research in urologic oncology. In the management of kidney and bladder cancer, he has special expertise in organ preservation and reconstructive surgery to maximize quality of life. Dr. McKiernan's research has been published in Cancer, Cancer Research, the Journal of Clinical Oncology, JAMA Oncology, Journal of Urology, Urologic Oncology, and Urology. He has authored and co-authored more than 220 scientific articles and book chapters on urologic cancer and related issues.For the past 10 years, he has directed a research team at Columbia University Medical Center investigating quality outcomes and effectiveness in urologic cancer surgery. He has served as the Vice Chairman for the AJCC TNM Staging Task Force, Co-Chair of the AUA Guidelines Panel on non-muscle invasive bladder cancer, as well as on the American Board of Urology and Society of Urologic Oncology Examination Committees. In addition, Dr. McKiernan is the principal investigator of the NIH-funded clinical trials program of experimental therapeutics in bladder cancer at Columbia University/NYPH, which is investigating new agents for bladder preservation in patients whose cancer has recurred after standard therapy. In collaboration with researchers at Columbia's Herbert Irving Comprehensive Cancer Center, his team continues to develop new therapeutic strategies for managing bladder cancer. Dr. Mckiernan is rated as a Distinguished provider by MediFind in the treatment of Clear Cell Sarcoma. His top areas of expertise are Bladder Cancer, Muscle Invasive Bladder Cancer, Urothelial Cancer, Cystectomy, and Nephrectomy.

Nicholas Karanikolas is an Oncologist and a Urologist in Staten Island, New York. Dr. Karanikolas is rated as a Distinguished provider by MediFind in the treatment of Clear Cell Sarcoma. His top areas of expertise are Renal Cell Carcinoma (RCC), Chromophobe Renal Cell Carcinoma, WT1-Related Wilms Tumor Syndromes, Ureteroscopy, and Prostatectomy.

Benjamin A. Gartrell, MD, is Director, Genitourinary Malignancy Program at Montefiore and an Assistant Professor of Oncology and Urology at our Albert Einstein College of Medicine. Since joining the Montefiore team in 2012, his expertise has been in treating genitourinary malignancies including prostate cancer, bladder cancer, renal cell cancer, and testicular cancer. He is also very active in translating science findings in collaboration with research colleagues at Einstein. In 2000, Dr. Gartrell received his Bachelor of Arts in Chemistry at the College of Wooster in Ohio. Following this, he attended the Northwestern University?s Feinberg School of Medicine, in Chicago, Illinois, where he received his Doctor of Medicine in 2005. His postgraduate training began in 2005 with an internship and residency in Internal Medicine at Case Western Reserve University, which he completed in 2008. He then completed a fellowship in Hematology/Oncology at Mount Sinai School of Medicine in 2012 and became Chief Fellow from 2010-2011. With a vast range of research interests, Dr. Gartrell focuses on translational research evaluating the significance of a novel immune checkpoint molecule in bladder cancer, evaluating the role of the autonomic nervous system in?prostate cancer, toxicities associated with anticancer therapies, and the impact of bone metastasis on patients with prostate cancer. His work has been published in a number of peer-reviewed journals, including the Journal of Clinical Oncology, Urologic Oncology, and European Urology. Dr. Gartrell also participates in community outreach to promote Prostate Cancer Awareness. Dr. Gartrell is rated as a Distinguished provider by MediFind in the treatment of Clear Cell Sarcoma. His top areas of expertise are Prostate Cancer, Renal Cell Carcinoma (RCC), WT1-Related Wilms Tumor Syndromes, Clear Cell Sarcoma, and Nephrectomy.

Nick Liu is a Urologist in Hoboken, New Jersey. Dr. Liu has been practicing medicine for over 17 years and is rated as an Advanced provider by MediFind in the treatment of Clear Cell Sarcoma. His top areas of expertise are Non-Muscle Invasive Bladder Cancer, Muscle Invasive Bladder Cancer, Obstructive Uropathy, Ureteroscopy, and Cystectomy. Dr. Liu is currently accepting new patients.

Jim Hu is a Urologist in New York, New York. Dr. Hu is rated as an Experienced provider by MediFind in the treatment of Clear Cell Sarcoma. His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Bladder Cancer, Prostatectomy, and Nephrectomy.

Dmitriy Zamarin is an Oncologist in New York, New York. Dr. Zamarin is rated as an Experienced provider by MediFind in the treatment of Clear Cell Sarcoma. His top areas of expertise are Endometrial Cancer, Ovarian Cancer, Ovarian Carcinosarcoma, and Sertoli-Leydig Cell Tumor.

Bobby Liaw is a Hematologist and an Oncologist in New York, New York. Dr. Liaw is rated as an Advanced provider by MediFind in the treatment of Clear Cell Sarcoma. His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Myxoid Liposarcoma, and Adult Soft Tissue Sarcoma. Dr. Liaw is currently accepting new patients.

Erik Goluboff is a Urologist in New York, New York. Dr. Goluboff is rated as an Advanced provider by MediFind in the treatment of Clear Cell Sarcoma. His top areas of expertise are Urothelial Cancer, Bladder Cancer, Muscle Invasive Bladder Cancer, Reconstructive Urology Surgery, and Nephrectomy.